| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study LA Carey, CM Perou, CA Livasy, LG Dressler, D Cowan, K Conway, ... Jama 295 (21), 2492-2502, 2006 | 4999 | 2006 |
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes LA Carey, EC Dees, L Sawyer, L Gatti, DT Moore, F Collichio, DW Ollila, ... Clinical cancer research 13 (8), 2329-2334, 2007 | 2795 | 2007 |
| The molecular portraits of breast tumors are conserved across microarray platforms Z Hu, C Fan, DS Oh, JS Marron, X He, BF Qaqish, C Livasy, LA Carey, ... BMC genomics 7, 1-12, 2006 | 1870 | 2006 |
| Molecular classification and molecular forecasting of breast cancer: ready for clinical application? JD Brenton, LA Carey, AA Ahmed, C Caldas Journal of clinical oncology 23 (29), 7350-7360, 2005 | 1324 | 2005 |
| De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 G Curigliano, HJ Burstein, EP Winer, M Gnant, P Dubsky, S Loibl, ... Annals of Oncology 28 (8), 1700-1712, 2017 | 1240 | 2017 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1225 | 2018 |
| Epidemiology of basal-like breast cancer RC Millikan, B Newman, CK Tse, PG Moorman, K Conway, LV Smith, ... Breast cancer research and treatment 109, 123-139, 2008 | 1193 | 2008 |
| Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete … WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, ... Journal of clinical oncology 33 (1), 13, 2015 | 1146 | 2015 |
| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1058 | 2020 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1025 | 2020 |
| Triple-negative breast cancer: disease entity or title of convenience? L Carey, E Winer, G Viale, D Cameron, L Gianni Nature reviews Clinical oncology 7 (12), 683-692, 2010 | 958 | 2010 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 945 | 2018 |
| 3rd ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 3) F Cardoso, A Costa, E Senkus, M Aapro, F André, CH Barrios, J Bergh, ... The Breast 31, 244-259, 2017 | 875 | 2017 |
| Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. KH Allison, MEH Hammond, M Dowsett, SE McKernin, LA Carey, ... | 869 | 2020 |
| Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer CK Anders, LA Carey Clinical breast cancer 9, S73-S81, 2009 | 864 | 2009 |
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ... New England Journal of Medicine 372 (2), 134-141, 2015 | 858 | 2015 |
| Sacituzumab govitecan in metastatic triple-negative breast cancer A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... New England journal of medicine 384 (16), 1529-1541, 2021 | 837 | 2021 |
| Phase II trial of bicalutamide in patients with androgen receptor–positive, estrogen receptor–negative metastatic breast cancer A Gucalp, S Tolaney, SJ Isakoff, JN Ingle, MC Liu, LA Carey, K Blackwell, ... Clinical cancer research 19 (19), 5505-5512, 2013 | 822 | 2013 |
| Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals A Flanagin, LA Carey, PB Fontanarosa, SG Phillips, BP Pace, ... Jama 280 (3), 222-224, 1998 | 736 | 1998 |
| Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer A Prat, B Adamo, MCU Cheang, CK Anders, LA Carey, CM Perou The oncologist 18 (2), 123-133, 2013 | 717 | 2013 |
